Pterostilbene for Cholesterol

Verdict: Taiwan Regulatory Restriction

Across 6 PubMed studies, the evidence for Pterostilbene in Cholesterol grades Tier D — counter-evidence.

D 🔴 D Counter-Evidence Taiwan Regulatory Restriction

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.39

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

D · Taiwan Regulatory Restriction

Confidence

77%

Broadly consistent

Evidence level

Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive

L1 ExamineGlobal benchmark

0.10

L11 AI re-checkIndependent read

0.30

L2 PubMedPrimary literature

0.40

L3 MechanismPlausibility

0.50

L5 Clinical bodiesAuthoritative stance

0.50

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.39
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 無高階證據可裁決
tier_strict_requirement_check — D 級條件未達 (需 E1-E3 negative；實際 E6)
detect_disputes — 偵測到 0 個 hard + 2 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial (Riche)

PMID: 25057276 2014 RCT (double-blind) n = 80

Finding: Pterostilbene monotherapy SIGNIFICANTLY INCREASED LDL by 17.1 mg/dL (p=0.001); LDL rise was attenuated/abolished when combined with grape extract (p=0.47) and when subjects were on baseline statin therapy. BP reduced (SBP -7.8, p<0.01; DBP -7.3, p<0.001).

⚠️ Industry-funded Effect size: LDL MD +17.1 mg/dL (p=0.001) — adverse direction for cholesterol endpoint

View on PubMed

Analysis of safety from a human clinical trial with pterostilbene (Riche, companion safety paper)

PMID: 23431291 2013 RCT (double-blind) n = 80

Finding: Pterostilbene generally safe up to 250 mg/day on biochemical safety markers; no adverse signal on liver/kidney/glucose; but does not refute the LDL-raising effect reported in the companion efficacy paper.

⚠️ Industry-funded

View on PubMed

Pterostilbene raises low density lipoprotein cholesterol in people (Brenner & Boileau, letter)

PMID: 30482564 2019 Cross-sectional

Finding: Letter (Clin Nutr) argues NR+pterostilbene combination produces a DOSE-DEPENDENT, statistically significant rise in total cholesterol driven entirely by LDL-C increase, replicating the Riche 2014 signal; ChromaDex subsequently halted new pterostilbene orders.

⚠️ Industry-funded Effect size: Re-analysis of Dellinger 2017 data: dose-dependent LDL-C rise (specific delta not in abstract; reported in supplementary of cited trial)

View on PubMed

Repeat dose NRPT (nicotinamide riboside + pterostilbene) increases NAD+ levels in humans safely and sustainably (Dellinger / Elysium Basis)

PMID: 29184669 2017 RCT (double-blind) n = 120

Finding: Primary endpoint: NAD+ increased ~40% (1X) and ~90% (2X). Main paper reports overall safety; Brenner 2019 re-analysis flagged a dose- and time-dependent LDL-C INCREASE in NRPT arms not seen with NR alone, consistent with pterostilbene-driven effect.

⚠️ Industry-funded Effect size: LDL-C increase dose-dependent (re-analysis); main paper p-values for LDL not in abstract

View on PubMed

A Short-Term Safety Evaluation of Silbinol(R) (Pterocarpus marsupium extract, 90% pterostilbene) in Healthy Adults

PMID: 37671486 2023 RCT (double-blind) n = 60

Finding: Lipid profile (TC, LDL, VLDL, TG) remained WITHIN NORMAL RANGE in all participants with no significant between-group difference vs placebo; no adverse signal on LDL at 200 mg/day in healthy subjects over 8 weeks. Does not replicate Riche 2014 LDL rise, but enrolled different population (healthy normolipidemic vs hypercholesterolemic) and lower dose.

⚠️ Industry-funded Effect size: No significant lipid change (p-values not in abstract)

View on PubMed

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial

PMID: 36082508 2023 RCT (double-blind) n = 111

Finding: Primary endpoint (hepatic fat) not significantly different vs placebo; reduced hepatic inflammation markers. Abstract does not report LDL-C changes specifically; longer 6-month NRPT exposure trial provides additional cardiometabolic safety signal but no published meta-analysis yet aggregates LDL data.

⚠️ Industry-funded

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA

Cautious

There were no records found that match your search criteria in this inventory. source↗

L4b EU EFSA

Cautious

Pterostilbene (Pterocarpus santalinus) extract (≥ 99%) ... assessed as novel and not authorized for use in food or food supplements unless a pre-market novel food authorisation is granted. source↗

L4e WHO

Cautious

Pterostilbene — CAS 537-42-8 — listed in Health Canada Natural Health Products Ingredients Database (NHPID) as an approved Schedule 1 'isolate' ingredient; source organism cited as Pterocarpus marsupium (stem heartwood). Multiple NPN-licensed products in the LNHPD (e.g. Nutracentials Blueberry Pterostilbene NX, NPN 80052455, containing pTeroPure® pterostilbene 25 mg; Ensonkan NMN+PQQ+Pterostilb… source↗

L5a NIH Office of Dietary Supplements

Cautious

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬6 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-cholesterol-INT-pterostilbene-001 繁體中文版 →